All News

This slideshow breaks down data on American Board of Urology certification and recertification among respondents of the 2014 Urology Times State of the Specialty survey.

Here are the AUA 2015 take-home messages on sexual/dysfunction, presented by Landon Trost, MD.

Two recently published studies significantly contribute to current knowledge regarding testosterone therapy and cardiovascular health, says one expert urologist.

The cost of radiation therapy for prostate cancer in the United States varies substantially, and most of the variation is accounted for by factors that are not related to the patient or tumor, according to the results of a study published online in Journal of Oncology Practice (Aug. 11, 2015).

A newly identified subset of prostate cancer biomarkers could help explain why African-American men are more likely than European-American men to develop and die from prostate cancer.

Middle-aged and older men undergoing testosterone replacement therapy aren’t at increased risk of venous thromboembolism (VTE), the results of a large comparative case-control analysis published online in Mayo Clinic Proceedings (July 15, 2015) suggest.

A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.

The three most commonly performed sling procedures exhibit long-term success, according to a recent observational study presented at the AUA annual meeting in New Orleans.

With conflicting data, should docetaxel be used up front in newly diagnosed metastatic disease?

Docetaxel (Taxotere) added to standard hormone therapy extended mean survival by about 10 months, according to a recent large-scale study.

In nearly every survey of physician sentiment, doctors cite administrative burdens associated with payer relations as distracting from patient care and the performance of their chosen profession.

“It is a positive thing, because the technology we’re using now is not really very accurate," one urologist told Urology Times.

“It is a positive thing, because the technology we’re using now is not really very accurate," one urologist told Urology Times.

A urologist in academic practice recently told Henry Rosevear, MD, that it’s impossible to simultaneously be an excellent clinician and a businessman. "I disagreed," Dr. Rosevear writes. "Emphatically."

In this interview, Inderbir S. Gill, MD, MCh, discusses what he calls the three most significant advances in minimally invasive oncologic surgery, how the current model for education can be improved, and the next frontier in minimally invasive surgery.

Raoul S. Concepcion, MD, uses his group's experience to illustrate how other urology groups can successfully incorporate APPs into their practice model and provide state-of-the-art care.

In this round-up of new urology products and services, learn about an app that helps moviegoers with OAB, a new mesh for sacrocolpopexy, and device/smartphone app that help women with pelvic floor exercises.

According to a population-based assessment of the risk factors for bladder slings used to treat stress urinary incontinence in women, provider volume impacts the incidence of mesh removal or revision.

Innovation has been the underpinning of American medicine for decades. However, as we move deeper into the 21st century, it is important to assess whether we are providing an environment where a culture of innovation can thrive.

Unfortunately, there is no “one-size-fits-all” answer to when you should start receiving Social Security benefits.

The AUA Coding and Reimbursement Committee, American Academy of Pediatric Urology, urology fellows of the American Academy of Pediatrics, and members of the Pediatric Urology Coordinating Council of the Society of Pediatric Urology recently published a consensus document on suggested coding guidance for pediatric hypospadias repair.

For the practicing physician, MACRA introduces a new fork in the road and a freeway to the future.

The reality of ICD-10 and what it means to physicians’ practices will come into focus beginning Oct. 1. But there are things that specifically urologists should know in the days, weeks, and dwindling months before adopting the code set becomes the new normal.

In most states, the standard for obtaining consent includes discussion of risks versus benefits, some known complications, and any alternative treatment options.

Congress doesn’t appear to like very much President Obama’s FY 2016 budget proposal to eliminate funding for Centers for Disease Control and Prevention activities that are focused on education about prostate cancer screening and treatment, as well as tracking disease incidence and mortality data.

This article focuses on the the Centers for Medicare & Medicaid Services' recently released 2013 utilization and payment data and what they tell us about the business of urology.

A novel investigational oral testosterone replacement therapy restored and maintained testosterone levels to a eugonadal range in 88% of hypogondal men treated with the agent in a randomized clinical trial.

ARN-509, a novel oral antiandrogen, was safe, well tolerated, and showed promising efficacy in men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC) in a phase II study, reported Neal D. Shore, MD.